Affiliation:
1. Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences University of Copenhagen 2100 Copenhagen Denmark
Abstract
AbstractThe 57‐mer full‐length GPR15L(25‐81) peptide has been identified as the principal endogenous agonist of the G protein‐coupled receptor GPR15. Its main activity resides in the C‐terminal 11‐mer GPR15L(71‐81), which has full efficacy but ~40‐fold lower potency than the full‐length peptide. Here, we systematically investigated the structure–activity relationship of GPR15L(71‐81) by truncations/extensions, alanine‐scanning, and N‐ and C‐terminal capping. The synthesized peptide analogues were tested at GPR15 stably expressed in HEK293A cells using a homogenous time‐resolved Förster resonance energy transfer‐based Gi cAMP functional assay. We show that the C‐terminal α carboxyl group and the residues Leu78, Pro75, Val74, and Trp72 are critical for receptor interaction and contribute significantly to the peptide potency. Furthermore, we tested the ability of GPR15L(71‐81), C‐terminally amidated GPR15L(71‐81), and GPR15L(25‐81) to activate the three GPR15 receptor mutants in a bioluminescence resonance energy transfer‐based G protein activation assay. The results demonstrate that the Lys192 and Glu272 residues in GPR15 are important for the potency of the GPR15L peptide. Overall, our study identifies critical residues in the peptide and receptor sequences for future drug design.
Funder
H2020 European Research Council
China Scholarship Council
Novo Nordisk Fonden
Carlsbergfondet
Lundbeckfonden
Subject
Pharmacology,Toxicology,General Medicine
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献